Sperm penetration at the maturing metaphase I stage can trigger oocyte activation in a mouse model
Reproductive BioMedicine Online · 2024
DOI: 10.1016/j.rbmo.2024.104329 ↗Kurz gefasst
Fachartikel in der Zeitschrift Reproductive BioMedicine Online, 2024. Verfasst von Ching-Chien Chang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Reproductive Biology Associates, Atlanta, GA, USA. Hauptthemen laut MEDLINE: Metaphase, Oocytes, Mice, Inbred ICR, Fertilization in Vitro. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
RESEARCH QUESTION: Can spermatozoa penetrate maturing metaphase I (MI) oocytes, and render subsequent development following conventional IVF in a mouse model? DESIGN: ICR mice were used in this study. Metaphase II (MII) cumulus-oocyte complexes (COC) harvested 15 h after injection of human chorionic gonadotrophin (HCG) were used for IVF as the control group (Group 1). In the treatment group (Group 2), maturing MI COC harvested 7 h after HCG injection were used for IVF. Fertilization, pronuclear formation, cleavage, blastocyst formation, DNA methylation status, chromosome number and live birth rates were used to evaluate the developmental dynamics and competency of maturing MI oocytes following conventional IVF. RESULTS: Maturing MI COC were fertilized using conventional IVF, and sperm penetration at MI-telophase I triggered oocyte activation. Most embryos resulting from fertilized MI oocytes developed to blastocyst stage during preimplantation development, albeit a substantial proportion of them were triploids due to the absence of the second meiotic division. Some of the embryos derived from fertilization of maturing oocytes were able to implant and gave rise to full-term development. CONCLUSION: Maturing MI COC from follicles before ovulation could be used for mouse IVF, and fertilized MI oocytes had high potential for development. Healthy offspring can be generated from maturing MI COC following conventional IVF. MI COC may represent a valuable source of 'usable' biomaterial in assisted reproduction. However, many embryos derived from MI COC via IVF have abnormal chromosome numbers in the mouse model. The implications of these findings for human IVF remain to be investigated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Reproductive Biology Associates, Atlanta, GA, USA.
- Institute of Biotechnology, National Taiwan University, Taipei, Taiwan, Republic of China.
- Center for Advanced Models for Translational Sciences and Therapeutics, University of Michigan Medical School, Ann Arbor, MI, USA.
- Nuwa Fertility Centre, Taiwan, Taipei, Republic of China.
- Nuwa Fertility Centre, Taiwan, Taipei, Republic of China. Electronic address: d95642001@gmail.com.
- Institute of Biotechnology, National Taiwan University, Taipei, Taiwan, Republic of China; Centre for Developmental Biology and Regenerative Medicine, National Taiwan University, Taipei, Taiwan, Republic of China; Agric…
Zitieren
APA
Chang, C. C., Peng, M., Tsai, L. K., Chang, C. C., Li, C. J., Wu, C. K., Chien, C. C., Xu, J., Nagy, Z. P., Liu, C. H., Lu, C. H., & Sung, L. Y. (2024). Sperm penetration at the maturing metaphase I stage can trigger oocyte activation in a mouse model. Reproductive BioMedicine Online. https://doi.org/10.1016/j.rbmo.2024.104329
Vancouver
Chang CC, Peng M, Tsai LK, Chang CC, Li CJ, Wu CK, et al. Sperm penetration at the maturing metaphase I stage can trigger oocyte activation in a mouse model. Reproductive BioMedicine Online. 2024. doi:10.1016/j.rbmo.2024.104329
BibTeX
@article{Chang2024,
author = {Chang, Ching-Chien and Peng, Min and Tsai, Li-Kuang and Chang, Chia-Chun and Li, Chia-Jung and Wu, Chia-Kuan and Chien, Chin-Cheng and Xu, Jie and Nagy, Zsolt Peter and Liu, Chi-Hong and Lu, Chung-Hao and Sung, Li-Ying},
title = {Sperm penetration at the maturing metaphase I stage can trigger oocyte activation in a mouse model},
journal = {Reproductive BioMedicine Online},
year = {2024},
doi = {10.1016/j.rbmo.2024.104329}
}
EUVIMED